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Abstract 
Great progress has been made in recent years to reduce the high level of suffering caused by malaria worldwide. 
Notably, the use of insecticide-treated mosquito nets for malaria prevention and the use of artemisinin-based 
combination therapy (ACT) for malaria treatment have made a significant impact. Nevertheless, the development 
of resistance to the past and present anti-malarial drugs highlights the need for continued research to stay one step 
ahead. New drugs are needed, particularly those with new mechanisms of action. Here the range of anti-malarial 
medicines developed over the years are reviewed, beginning with the discovery of quinine in the early 1800s, through 
to modern day ACT and the recently-approved tafenoquine. A number of new potential anti-malarial drugs currently 
in development are outlined, along with a description of the hit to lead campaign from which it originated. Finally, 
promising novel mechanisms of action for these and future anti-malarial medicines are outlined.
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Background
In 2017, the World Health Organization (WHO) esti-
mated that there were 219 million cases of malaria world-
wide, an increase of 2 million from the previous year, and 
as a result there were 435 thousand deaths, or 1190 per 
day, mostly young children [1]. Encouragingly, since 2000, 
these figures have decreased by about 37% worldwide, 
but a number of recent reports have shown that this level 
is slowly plateauing, emphasizing that there must not be 
complacency with the current treatment and prevention 
strategies [2, 3]. There are five species of the Plasmodium 
parasite, with Plasmodium falciparum being the most 
prevalent in Africa and Plasmodium vivax being the 
most prevalent in countries outside Africa. Almost half 
the world’s population is at risk of contracting malaria, 
with Africa having the biggest share of cases and deaths 
of any continent ( ∼ 90%).
Over the past few years, a number of reviews have 
been published which evaluate the potential future of 
anti-malarial drugs. Of note: Triple-anti-malarial drug 
combinations were examined in 2014 [4]; a review on 
the numerous strategies currently used in anti-malarial 
drug discovery was published in early 2017 [5], and an in-
depth primer on all aspects of malaria was published in 
late 2017 [6]. In early 2018, a review was published high-
lighting the discovery and development of a number of 
new anti-malarial drug candidates [7, 8].
This review aims to summarize the past, present and 
future of compounds used to treat malaria. There is a 
focus on projects supported by the Medicines for Malaria 
Venture (MMV), a non-governmental organisation that 
maintains a website [9] highlighting collaborations from 
the very early stages of drug discovery and lead optimiza-
tion (e.g. the Open Source Malaria (OSM) project with 
which the authors are involved [10]), to the progression 
of lead compounds through clinical trials (e.g. Cipar-
gamin, which has been developed by Novartis [11]) and 
all the way to the final stages of bringing a drug to mar-
ket (e.g. Artesunate for injection, developed by Guilin 
Pharmaceutical). After a brief survey of past medicines, 
and those that are currently being used, focus will be put 
on compounds that are currently in development, and in 
particular the lead optimization campaigns of each. Since 
it is such a crucial component of modern anti-malarial 
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drug discovery, this review will end with a survey of the 
most promising mechanisms of action of those com-
pounds in development.
The scope of this review encompasses compounds 
described by the MMV survey of current anti-malari-
als, previous reviews on anti-malarial drugs, as well as 
compounds currently undergoing active clinical trials. 
The information presented in this review was obtained 
through structure searching of the relevant compounds 
in the SciFinder database. Additional references were 
found through the Web of Science database (Additional 
file 1).
Past
Since the isolation in 1820 of quinine, the first chemi-
cally purified effective treatment for malaria, a number 
of other natural and synthetic compounds have been 
developed (Fig. 1). However, as time passed, strains of the 
parasite began to show signs of resistance towards these 
drugs, rendering them less effective. Accordingly, their 
use has ceased or is restricted to particular situations.
Quinine
First isolated from the bark of the cinchona tree in 
1820, quinine has been used as one of the most effec-
tive treatments for malaria to date [12]. Resistance was 
first reported in the 1980s [13] and as of 2006, quinine is 
no longer used as a front-line treatment for malaria but 
is still on the WHO’s Model List of Essential Medicines 
(MLEM) [14] for the treatment of severe malaria in cases 
where artemisinins are not available.
Mepacrine
Mepacrine (a.k.a quinacrine) was predominantly used 
throughout the Second World War as a prophylatic, sold 
under the trade name Atabrine [15]. This compound is a 
derivative of methylene blue, another anti-malarial that 
was discovered in 1891 and found to be an effective treat-
ment for malaria [16, 17]. Its use has declined over the 
years but methylene blue and its derivatives are, how-
ever, the subject of increasing current interest [18] and 
it is currently in clinical trials as a combination with pri-
maquine (vide infra). Mepacrine itself is no longer used 
today due to the high chance of undesirable side effects 
such as toxic psychosis [19].
Chloroquine
During the 1940s, chloroquine (CQ) was used to treat 
all forms of malaria with few side effects [20]. Resist-
ance to CQ was first reported in the 1950s and over the 
years many strains of malaria have developed resist-
ance. Indeed, resistant strains (K1, 7GB, W2, Dd2, etc.) 
of the malaria parasite are now used in potency evalua-
tion assays as a way of showing efficacy [21]. Chloroquine 
is on the MLEM for the treatment of P. vivax in regions 
where resistance has not developed [14].
Mefloquine
Mefloquine was developed in the 1970s by the United 
States Army [22] and is still used today, also being one 
of the medicines on the MLEM. Originally introduced 
for the treatment of chloroquine-resistant malaria, it has 
been used as both a curative and a prophylactic drug. 
Resistance was first reported in 1986 [23]. It is thought 
that the structurally related quinoline drugs (such as 
quinine, mepacrine, chloroquine and mefloquine) act 
through the disruption of haemoglobin digestion in the 
blood stage of the parasite [24]. These drugs are com-
monly used in combination with a complementary drug 
(e.g. mefloquine and artesunate, sold as Artequin™) to 
reduce the chance of resistance development to the quin-
oline family of compounds. Mefloquine is commonly sold 
in its racemic form under the brand name Lariam®, how-
ever it is no longer widely used due to the perception of 
central nervous system toxicity that has been suggested 
to affect a large number of its users [25].
Halofantrine
Developed between the 1960s and 1970s by the Walter 
Reed Army Institute of Research [26], halofantrine was 
initially used for treatment against all forms of the Plas-
modium parasite. Its use has diminished over time due to 
a number of undesirable side effects, such as the poten-
tial for high levels of cardiotoxicity. It is only used as a 
Fig. 1 Well known anti-malarial medicines discovered between 
1820 and the 1980s. Some are still used today while some have 
been rendered ineffective due to development of resistant strains 
or the emergence of undesirable side effects. Dates of first reported 
resistance are shown in brackets
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curative drug and not for prophylaxis due to the high tox-
icity risks and its unreliable pharmacological properties. 
Halofantrine is still used today, under the brand name 
Halfan™, but only in cases where patients are known 
to be free of heart disease and where infection is due to 
severe and resistant forms of malaria [27].
Present
On the WHO Model List of Essential Medicines [14], 
there are currently listed 14 medicines for curative treat-
ment of malaria and 4 medicines for prophylactic treat-
ment, with the treatments formulated either as single 
compounds or as combinations. Perhaps the most effec-
tive of these are the artemisinin-based combinations 
which use an artemisinin derivative (short-acting) in 
combination with one or more complementary com-
pounds (long-acting and possessing different mecha-
nisms of action).
MMV have been involved in progressing nine new 
anti-malarial treatments based on different formulations/
combinations of approved drugs (Fig.  2). All of these 
compounds are on the MLEM as combination therapies.
Artemisinin and its derivatives
Artemisinin was first isolated in 1971 by Tu Youyou 
from the plant Artemisia annua, a herb that has com-
monly been used in Chinese traditional medicine [28]. 
Due to the great positive impact of artemisinin in com-
bating malaria, Youyou was awarded the joint Nobel 
Prize in Physiology or Medicine in 2015 for “her discov-
eries concerning a novel therapy against malaria” [29]. 
Artemisinin has been shown to be efficacious against all 
multi-drug resistant forms of P. falciparum. The most 
common derivatives of artemisinin are artemether, 
artesunate and arteether. These semi-synthetic deriva-
tives are prodrugs which are transformed to the active 
metabolite, dihydroartemisinin. The use of artemisinins 
has been integral in the fight against malaria with ACT 
making up the majority of modern day treatments [30]. 
Although slow to develop, the first report of resistance to 
artemisinin was in western Cambodia in 2008 [31]. Ten 
years later, in February of 2018, a report was published 
identifying more than 30 independent cases of arte-
misinin resistance in southeast Asia, specifically with 
resistance to the dihydroartemisinin–piperaquine combi-
nation therapy [32].
The mechanism of action (MoA) through which arte-
misinin acts has been widely debated [33]. The most 
accepted theory is that the molecule is activated by haem 
to generate free radicals, which in turn damage proteins 
required for parasite survival [34, 35]. Still, evidence 
for a number of other possible mechanisms have been 
found. In 2013, a computational approach was taken 
to determine the MoA based around previous studies 
which identified haem and PfATP6  (Ca2+ transporter) as 
potential MoAs [36]. More recently in 2015, artemisinin 
was shown to be associated with the up-regulation of the 
unfolded protein response (UPR) pathways which may be 
Fig. 2 New drug combinations/formulations that have been approved for use. Brand name of the drug (in bold), partnered company (in italics) and 
drug combination (colour-coded to the structures) are listed
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linked to decreased parasite development [37]. Another 
study showed that artemisinin was is a potent inhibitor 
of P. falciparum phosphatidylinositol-3-kinase (PfPI3K) 
[38].
Amodiaquine
Amodiaquine was first synthesized in 1948 [39]. It 
is mainly used for the treatment of uncomplicated P. 
falciparum malaria when used in combination with 
artesunate and is commonly sold under the trade name 
Camoquine® or Coarsucam™ [40]. Similar to chloro-
quine, amodiaquine’s MoA is thought to involve com-
plexation with haem and inhibition of haemozoin 
formation [41].
Piperaquine
Piperaquine was developed in the 1960s as a part of the 
Chinese National Malaria Elimination Programme [42]. 
Initially used throughout China as a replacement for 
chloroquine, resistance led to its diminished use as a 
monotherapy. While the MoA of piperaquine is not com-
pletely understood, studies have suggested that it acts 
by accumulating in the digestive vacuole and inhibiting 
haem detoxification through the binding of haem-con-
taining species [30, 43]. These days, piperaquine is used 
as a partner drug with dihydroartemisinin (commonly 
sold under the trade name Eurartesim®).
Lumefantrine
Lumefantrine (a.k.a. benflumetol) was first synthesized 
in 1976 as a part of the Chinese anti-malarial research 
effort “Project 523” which also resulted in the discovery 
of artemisinin [44]. It is currently sold under the trade 
name Coartem®. The exact MoA of lumefantrine is 
unknown, however studies suggest that it inhibits nucleic 
acid and protein synthesis through the inhibition of β
-haematin formation by complexation with haemin [41]. 
Lumefantrine is currently used only in combination with 
artemether.
Proguanil and atovaquone
Proguanil was first reported in 1945 as one of the first 
antifolate anti-malarial drugs [45], while atovaquone 
was first reported in 1991 for the treatment of protozoan 
infections [46]. The combination of these, commonly 
sold as Malarone™, has been marketed by GlaxoSmith-
Kline (GSK) since the early 2000s, and has proven to be 
a very effective anti-malarial due to the synergistic effect 
of the two components. This is, in large part, due to the 
different MoAs for each compound. Atovaquone acts as 
a cytochrome bc1 complex inhibitor which blocks mito-
chondrial electron transport [47]. Proguanil (when used 
alone) acts as a dihydrofolate reductase (DHFR) inhibitor 
through its metabolite, cycloguanil (CG) which disrupts 
deoxythymidylate synthesis. When used in combination 
with atovaquone however, proguanil does not act as a 
DHFR inhibitor but has instead been shown to reduce 
the concentration of atovaquone required for treatment 
[48]. Generic atovaquone/proguanil is still available today 
for the treatment of chloroquine-resistant malaria.
Pyrimethamine and sulfadoxine
Pyrimethamine (PYR) was developed in the early 1950s 
by Gertrude Elion and George Hitchings and is now 
sold under the trade name Daraprim™ [49]. The devel-
opment of pyrimethamine was a part of the efforts that 
won Elion, Hitchings and Black the joint Nobel Prize in 
Physiology or Medicine in 1988 for “their discoveries of 
important principles for drug treatment” [50]. Sulfadox-
ine was developed in the early 1960s [51]. It is no longer 
used as a preventative drug due to high levels of resist-
ance. The combination of pyrimethamine and sulfadox-
ine was approved for use for the treatment of malaria in 
1981 and is now commonly sold under the trade name 
Fansidar®. Both drugs are known to target the parasite 
folate biosynthesis pathway [52]. Pyrimethamine inhibits 
dihydrofolate reductase, while sulfadoxine inhibits dihy-
dropteroate synthetase.
Pyronaridine
Pyronaridine was first synthesized in the 1970s at the 
Institute of Chinese Parasitic Disease [53, 54]. It has been 
found to be efficacious against chloroquine resistant 
strains and has been in use for over 40 years, sold under 
the trade name Pyramax® (in combination with artesu-
nate). Like lumefantrine, pyronaridine has been found to 
act through the inhibition of β-haematin formation [55].
Tafenoquine
First discovered in 1978 at the Walter Reed Army 
Institute of Research, Tafenoquine (TQ) was recently 
approved by the United States Food and Drug Adminis-
tration for use as the first new single-dose for the radical 
treatment of P. vivax malaria in over 60 years [56]. TQ 
is thought to be a prodrug which is metabolized to the 
active quinone TQ, however the MoA is not well known 
[57]. It is currently sold under the brand name Krintafel.
Future
Since its establishment in 1999, the Medicines for 
Malaria Venture has been frontlining the discovery and 
development of new medicines for the treatment of 
malaria. The potential for these compounds to act as new 
anti-malarials is judged by a number of requirements: 
novel modes of action with no cross-resistance to current 
drugs; single-dose cures (artesunate and chloroquine are 
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unable to do this); activity against both the asexual blood 
stages that cause disease and the gametocytes responsi-
ble for transmission; compounds that prevent infection 
(chemoprotective agents); and compounds that clear P. 
vivax hypnozoites from the liver (anti-relapse agents) 
[59, 60]. MMV has been aiding the fight against malaria 
by partnering with universities and pharmaceutical com-
panies around the world to bring new anti-malarials to 
market (Fig. 3).
Besides the traditional drug discovery and develop-
ment methods for the identification of new anti-malar-
ials that will be described below, there are a number 
of other ways in which a new anti-malarial drug may 
be discovered. One way, as previously mentioned, is 
through the exploration of new combinations and for-
mulations of current anti-malarial drugs. This may 
help overcome issues with resistance to a particular 
component or may assist in the delivery of the drug 
allowing it to be more effective. Alternatively, existing 
drugs used for other purposes may be found efficacious 
against malaria and subsequently be repurposed as a 
new anti-malarial treatment. This can be advantageous 
since these compounds may have already shown good 
biological properties and may also reveal novel MoAs. 
Examples include those shown in Fig. 4.
Methylene blue, a drug for the treatment of methae-
moglobinemia. Last completed Phase II trials in 2017 
(NCT02851108) as a combination with primaquine. 
Fosmidomycin, an antibiotic. Most recently in Phase 
II trials in 2015 (NCT02198807) as a combination with 
piperaquine. Rosiglitazone, an antidiabetic drug. Cur-
rently in clinical trials as an adjunctive therapy for severe 
malaria (NCT02694874). Imatinib, a cancer therapy 
drug. Currently in Phase II trials (NCT03697668) as a 
triple combination with dihydroartemisinin-piperaquine. 
Sevuparin, a drug for the treatment of sickle cell disease. 
Fig. 3 Snapshot of the projects supported by MMV at different stages of the drug discovery and development pipeline (Adapted from the 
MMV-supported projects webpage [58])
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Last in Phase I/II trials in 2014 (NCT01442168) as a 
combination with atovaquone-proguanil.
The following seven compounds were discovered and 
developed with the hope of progressing into clinical trials 
as potential new anti-malarial candidates (Fig.  5). How-
ever, over the past two years, progress in the develop-
ment of these compounds has slowed, making the fate of 
these drug candidates less clear.
The chiral 8-aminoquinoline derivative, NPC1161B 
was developed at the University of Mississippi and was 
still in preclinical studies in 2014 [61–64]. MK4815 was 
developed in 2012 at Merck but is still in preclinical stud-
ies due to safety issues [65]. CDRI 97/78 is a fast-acting 
novel trioxane anti-malarial first synthesized in 2001 by a 
team at the Council of Scientific and Industrial Research 
in India [66]. Having passed all preclinical studies, it was 
last seen to have completed first-in-human Phase I trials 
in 2014 [67]. Developed at the Liverpool School of Tropi-
cal Medicine in 2009, N-tert butyl isoquine/GSK369796 
was designed as an alternative to amodiaquine [68, 69]. 
It completed preclinical studies [70], and was last in 
Phase I trials in 2008 (NCT00675064). Artemisone is a 
second-generation semi-synthetic artemisinin deriva-
tive developed at the Hong Kong University of Science 
and Technology, that has previously been shown to be 
as efficacious as artesunate, with minimal neuro- and 
cytotoxicity and a comparably low cost of production 
[71]. It was withdrawn from Phase II/III trials in 2010 
(NCT00936767). The bisthiazolium salt, SAR97276, was 
discovered and developed by Sanofi in 2005 [72], how-
ever further investigation was terminated in 2012 after 
Phase II trials (NCT01445938). AQ-13 is a chloroquine 
derivative that was first described in 1946 [73]. While 
only differing to CQ in the amine side-chain, this differ-
ence has been linked to its increased efficacy against CQ-
resistant strains [74]. It has a MoA and pharmacokinetic 
properties similar to that of CQ [75, 76]. AQ-13 last com-
pleted Phase II trial at the end of 2017 (NCT01614964) 
[77], however there has been no mention of any follow-
ing active trials so the ongoing status of this compound 
is unclear.
The compounds in the remainder of this section are 
currently still actively being pursued. For ease of visuali-
sation throughout in this section, a graphical summary of 
each compound structure and its code will be displayed, 
along with key physical and biological properties identi-
fied during the hit to lead campaigns (Additional file 2).
Preclinical
Once a lead compound has been identified, optimization 
of the structure can begin. This largely involves investiga-
tion into the structure activity relationship (SAR) of the 
drug, optimising for properties such as potency (both 
in  vitro and in  vivo), solubility and metabolic stability. 
The candidate must also be assessed for any possible tox-
icity (e.g. dosing, cytotoxicity/genotoxicity levels, etc.).
M5717 (Fig.  6) was developed in 2015 by a team led 
by the Drug Discovery Unit (DDU) in Dundee and was 
shown to have potent activity against multiple stages 
of the Plasmodium parasite via a novel mechanism of 
action [78, 79].
Initial phenotypic screening of the Dundee pro-
tein kinase scaffold library against the 3D7 
Fig. 4 New anti-malarial compounds in development as a result of 
drug repurposing. Original indications for the drugs are shown in 
parentheses. Many of these repurposed drugs are already in Phase II 
trials as new potential anti-malarials
Fig. 5 New anti-malarial drug candidates that have reported no 
significant progress in the last 2 years. These compounds may have 
encountered issues during preclinical or early clinical studies
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multi-drug-resistant P. falciparum strain identified a 
compound (M1, Fig.  7) that possessed high potency 
against the parasite, albeit with poor physicochemical 
properties. Optimization of this structure (via M2 and 
M3) led to improvements across the board (M5717).
In addition to the nanomolar activity against the 3D7 
strain, M5717 has shown almost equal potency against 
a number of other drug-resistant strains (K1, W2, 7G8, 
TM89C2A, D6 and V1/S) as well as similar potencies 
across multiple life cycle stages (liver schizonts, gameto-
cytes and ookinetes).
M5717 was found to be as effective as current anti-
malarial drugs (chloroquine, mefloquine, artemether, 
dihydroartemisinin and artesunate) when evaluated in 
the in vivo Plasmodium berghei mouse model for single-
dose efficacy showing > 99% reduction in parasitaemia at 
doses of 4 × 30 mg/kg p.o. q.d. and an ED90 of 0.1–0.3 mg/
kg.
Due to its novel MoA (PfeEF2 inhibition, vide infra) 
and its ability to clear blood-stage parasites completely, 
M5717 satisfies the requirements to be a long duration 
partner and could be used as part of a combination ther-
apy with a fast-acting compound [80]. Additionally, the 
compound has shown the ability to act as a transmission-
blocking drug (stage IV–V) and also to be effective for 
chemoprotection.
In late 2017, M5717 was cleared for progression from 
development to Phase I clinical trials for volunteers in 
Australia (NCT03261401).
Identified by AstraZeneca in 2015, MMV253 (Fig. 8) is 
a novel triaminopyrimidine (TAP) that has shown good 
in  vitro potency and in  vivo efficacy, and acts through 
another novel MoA [81].
High-throughput screening of 500,000 compounds 
from AstraZeneca’s library against blood stage P. falci-
parum resulted in the identification of a promising series 
of TAPs. The initial hit (M’1, Fig. 9) suffered from hERG 
inhibition and poor solubility which, through lead opti-
mization, was improved upon to give a compound that 
possessed high potency and desirable pharmacokinetic 
properties (MMV253).
When screened against numerous mutant resist-
ant strains with various mechanisms of resistance, 
MMV253 showed no spontaneous reduction in potency 
which can be attributed to its novel MoA (PfATP4 inhi-
bition, vide infra). Good in  vitro-in vivo correlation 
(IVIVC) was shown with a predicted human half-life 
of ∼ 36 h (which is long compared to another fast-kill-
ing drug, artemisinin, which has a human half-life of 1 
hour).
As of late 2016, the pharmaceutical company Cadila 
Healthcare owns the license for the compound series and 
is now doing further lead development in order to pro-
gress the drug through preclinical trials [82].
UCT943 (Fig.  10) was identified in 2016 by a team 
at the University of Cape Town, South Africa and is 
a key compound in a novel class of 2-aminopyrazine 
Fig. 6 Key biological and physical properties of M5717 
Fig. 7 Key stages in the hit to lead pathway of M5717. Initial 
replacement of Br for F, replacement of pyridine with ethylpyrrolidine, 
and addition of a morpholine fragment led to the optimized 
compound M5717 
Fig. 8 Key biological and physical properties of MMV253. logD and 
in vivo  ED90 kindly provided by V. Sambandamurthy, S. Hameed P. and 
S. Kavanagh, personal communication, 2018
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anti-malarials that has shown single dose curing ability 
in vivo and potential as a clinical candidate [83].
The original 3,5-diaryl-2-aminopyridine series was 
identified from a high-throughput screen of 36608 
compounds from the commercially available SoftFocus 
kinase library [84]. The initial hit (U1, Fig. 11) showed 
promising in  vitro activity against the drug-sensitive 
NF54 strain (IC50 = 49 nM) but suffered from poor 
solubility and high metabolic clearance. To address the 
poor measured in vivo stability, the labile hydroxy and 
methoxy groups were replaced by a single trifluorome-
thyl group (U2), but this change resulted in a significant 
loss of solubility. Significant improvements in solubility 
and potency were obtained by first replacing the mesyl 
group with a piperazine carboxamide group (U3) and 
subsequently introducing another nitrogen atom into 
the pyridine ring (UCT943) [85, 86].
In the P. berghei mouse model, UCT943 has shown 
the ability to cure malaria at doses of 4 × 10 mg/kg and 
has an ED90 of 1 mg/kg. Interestingly, another closely 
related molecule (with a nitrogen instead of a carbon 
in the red circle) which was evaluated during the SAR 
study, displayed similar in  vitro anti-malarial activity 
(IC50 = 9.1 nM) and solubility (198 µ M) but showed a 
complete lack of in vivo activity with a < 40% reduction 
in parasitaemia using a comparable dosage.
UCT943 is potent across multiple parasite life stages 
of both P. falciparum and P. vivax. Its target is Plas-
modium phosphatidylinositol-4-OH kinase (PfPI4K), 
which has also been implicated as the target for 
MMV048 (vide infra) [87]. UCT943 was in originally in 
place as a back-up to MMV048, however, due to pre-
clinical toxicity, this candidate has been withdrawn.
From a discovery process by Anacor Pharmaceuti-
cals that began in 2010 with a novel class of benzoxab-
orole anti-malarial compounds [88], AN13762 (Fig. 12) 
emerged in 2017 as the lead compound, showing excel-
lent activity in  vitro and in  vivo, multi-strain efficacy 
and the ability to perform as a rapid-acting drug [89].
By screening a library of boron-containing com-
pounds (previously shown to have selective activity 
against fungi, bacteria, parasites and inflammation) 
in a whole cell assay against P. falciparum, the initial 
hit compound, AN3661 (A1, Fig.  13), was identified 
to have potent in  vitro activity against the 3D7 strain 
(IC50 = 26 nM). Further SAR and optimization studies 
led to the development of A2 in which the alkylcarbox-
ylic acid chain was moved and replaced by a substituted 
pyrazine ether. This compound showed greater potency 
but still suffered from high metabolic clearance [90]. 
Replacement of the ester group with an amide group 
(A3) led to improved metabolic stability and bioavail-
ability, with a significant decrease in potency. Modifi-
cation of the primary amide to a cyclic tertiary amide, 
and introduction of a methyl group on the benzoxab-
orole gave the lead compound AN13762 which pos-
sessed improved potency and metabolic stability [89].
AN13762 has been shown to be equally potent across 
a wide range of drug resistant strains. The drug has dis-
played similar in vivo clearance rates when compared to 
artesunate. There is no inherent genotoxicity (as shown 
in Ames assays and in vivo rat micronucleus studies), and 
no cytotoxicity at concentrations up to 100 μM in human 
cell lines [89].
The precise mechanism of action for AN13762 remains 
unknown, though initial MoA studies on hit compound 
AN3661 identified a potential target as the P. falciparum 
cleavage and polyadenylation specificity factor (PfCPSF3) 
Fig. 9 Key stages in the hit to lead pathway of MMV253. Initial 
replacement of ethylbenzene on M’1 with 2-methylpyridine resulted 
in lower hERG affinity and improved solubility. Substitution of the 
pyrrolidine in M’2 with an imidazole containing an amine spacer 
further improved solubility and greatly improved the potency. 
Addition of an N-methyl group and a cyclopropane moiety led to the 
optimized compound MMV253 
Fig. 10 Key biological and physical properties of UCT943 
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[91]. AN13762 has proceeded into the preclinical phase, 
with first-in-human studies planned for 2019 [58].
Developed in 2017 by a team at Heidelberg University, 
SC83288 (Fig. 14) is an amicarbalide derivative that pos-
sesses a novel chemotype for current anti-malarials, may 
have a potentially new MoA and has shown the ability 
to be a fast-acting drug for the intravenous treatment of 
severe malaria [92].
An in silico screen of a library of small molecule com-
pounds for their ability to dock into P. falciparum lactate 
dehydrogenase led to the identification of amicarbalide 
(S1, Fig. 15), which was found to be highly potent (IC50 = 
10 nM) against the Dd2 strain [93]. In order to overcome 
a potential DNA binding effect, an amidine group was 
replaced with a sulfonamide linker leading to S2 which 
possessed better solubility and improved metabolic sta-
bility. Further modification of the other amidine group 
with a substituted piperazine ring (S3) led to improved 
potency and water solubility, but the compound suffered 
from poor permeability. Ultimately, replacement of the 
butyl chain with an acetyl group led to the highly potent 
lead compound SC83288.
SC83288 has been shown to be potent against a num-
ber of drug-resistant strains at IC50 values of < 20 nM and 
is also efficacious against early stage (I–III) gametocytes 
(IC50 = 199 nM) but not against late stage gametocytes 
(IV and V). It has an excellent safety profile, with no cyto-
toxicity, genotoxicity or hERG binding. In the Plasmo-
dium vinckei rodent malaria model, SC83288 was able to 
fully cure the infection at a dose of 4 × 20 mg/kg i.p. q.d. 
with no resurgence of infection. It is however, completely 
inactive against P. berghei.
While the exact MoA of SC83288 is unknown, the 
generation of resistant clones has identified PfATP6 as a 
possibly relevant target. However, it has been shown that 
SC83288 does not directly inhibit this target suggesting 
PfATP6 may have a less direct role in the mechanism of 
SC83288. PfMDR2 has been identified as another possi-
ble mechanism of resistance, facilitating the clearance of 
the drug from the parasite. SC83288 has been evaluated 
against artemisinins, showing no cross resistance and 
highlighting its potential as an alternative to artesunate 
for the treatment of severe malaria when combined with 
a slow-acting partner drug [94].
Discovered in 2010 by a team at Portland State Univer-
sity and further developed by DesignMedix, DM1157 
(Fig.  16) is part of a class of compounds known as 
“reversed chloroquines” (RCQs), designed to overcome 
chloroquine-resistant and chloroquine-sensitive strains 
of the malaria parasite. The compound has been shown 
to be efficacious in vitro and in vivo [95].
CQ resistance is known to be linked to the P. falci-
parum chloroquine resistance transporter (PfCRT): 
Fig. 11 Key stages in the hit to lead pathway of UCT943. Initial 
change the phenyl substituents with a single trifluoromethyl group 
led to greater in vivo stability. Introduction of piperazine amide 
instead of methylsulfonyl and a pyrazine instead of a pyridine led to 
the improved solubility and potency of the optimized compound. 
Surprisingly, introduction of a nitrogen in the red circle resulted in 
complete inactivity in vivo
Fig. 12 Key biological and physical properties of AN13762. Solubility 
kindly provided by Y.-K. Zhang, personal communication, 2018
Fig. 13 Key stages in the hit to lead pathway of AN13762. Initial 
replacement of the carboxylic acid chain with a pyrazine, and 
subsequent switch of the ester to a substituted amide helped to 
improve in vivo stability and bioavailability leading to the optimized 
compound
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mutations to this target facilitate the expulsion of CQ 
from the parasite. A class of molecules has been identi-
fied, so-called “reversal agents”, that can inhibit PfCRT, 
thus slowing the exportation of CQ from the parasite. By 
combining the chloroquinoline core of CQ (D1, Fig. 17) 
with the known reversal agent, imipramine, the first RCQ 
(D2) was designed, but this molecule suffered from poor 
bioavailability and metabolic stability [96]. Subsequent 
SAR studies resulted in the substitution of the imipra-
mine motif with a 1-(2,2-diphenylethyl)piperazine moi-
ety which led to a compound (D3) that was more stable 
to metabolic cleavage, but suffered from a high cLogP. 
In order to overcome this, the two phenyl groups were 
replaced with pyridines and the piperazine replaced with 
an aminopiperidine resulting in the lead compound, 
DM1157 that possessed a lower cLogP value (3.6) while 
still maintaining high potency against both CQ-resistant 
(Dd2 = 1.6 nM) and CQ sensitive strains (D6 = 0.9 nM) 
when compared to CQ (cLogP = 5.1, Dd2 = 102 nM, D6 
= 6.9 nM).
In a P. berghei rodent model, DM1157 showed good 
efficacy both orally and subcutaneously. Most notably, 
a > 99.9% reduction in parasitaemia was seen at an oral 
dose of 4 × 30 mg/kg with 2/3 mice cured 30 days post 
infection. DM1157 has also been evaluated against P. fal-
ciparum and P. vivax multi-drug resistant field isolates 
in Indonesia and was found to be threefold more potent 
than CQ in both species [97].
CQ is known to bind to heme and inhibit β-haemo-
zoin formation. DM1157 (and other RCQ compounds) 
have been shown also to act in this manner, but with 
much higher levels of inhibition of β-haemozoin both 
in vitro and in vivo. DM1157 is currently in Phase I tri-
als to evaluate its safety and pharmacokinetics in humans 
(NCT03490162).
Translational (human volunteers)
Upon the completion of preclinical trials, the drug will 
have either passed or failed the required safety standards 
and pharmacokinetic profiling. For a compound that has 
passed these requirements, trials may then be conducted 
in human volunteers in order to show its efficacy as a 
potential treatment.
P218 (Fig.  18), discovered by BIOTEC Thailand in 
2012, is an antifolate anti-malarial drug bearing resem-
blance to the 2,4-diaminopyrimidine core structure of 
PYR, and is highly selective for the P. falciparum dihydro-
folate reductase (PfDHFR) [98].
Unlike the typical high-throughput screening that is 
used for the identification of hit compounds in medicinal 
chemistry, P218 was identified through careful exami-
nation of the cocrystal structures of known PfDHFR 
inhibitors and their substrates. The initial observation 
Fig. 14 Key biological and physical properties of SC83288. In vivo 
 ED90 kindly provided by M. Lanzer, personal communication, 2018
Fig. 15 Key compounds in the discovery of SC83288. Initial 
modification of one amidino group with a sulfonamide linker (S2) 
resulted in improved solubility. Further modification of the remaining 
amidine group with substituted piperazine moieties ultimately led to 
the optimized compound with good solubility, permeability and high 
potency
Fig. 16 Key biological and physical properties of DM1157. CLint 
HLM and in vivo  ED90 kindly provided by D. Peyton, personal 
communication, 2018
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that 2,4-diaminopyrimidines acted as antagonists to folic 
acid led to the discovery and development of methotrex-
ate (MTX) as an antitumor drug (Fig.  19). By examin-
ing the binding interactions with DHFR, the structure 
of P65 was identified. A total of over 200 compounds 
(not described in the original report) were designed and 
synthesized after further examination of potential inter-
actions with amino acid residues, with the optimized 
structure of P218 being identified as the best compound.
The 2,4-diaminopyrimidine scaffold of P218 has been 
found to bind deep in the active site of PfDHFR in both 
wild-type and mutant strains. This, along with the hydro-
gen bonding interaction of the carboxylate group with an 
Arg residue at the opposite end of the active site results 
in tighter binding and a longer residence time when com-
pared to PYR. Since P218 is contained almost entirely 
within the dihydrofolate binding site, the strength of the 
binding should be strong enough to overcome any amino 
acid mutations, thus minimising the chance of drug-
resistant mutations to arise. The novel two-step mecha-
nism of action for binding to PfDHFR (vide infra) allows 
P218 to overcome resistance that has emerged from the 
use of pyrimethamine. P218 has also shown high selectiv-
ity to the binding of malarial over human DHFR, which 
translates into reduced toxicity.
In vivo studies have shown P218 to be highly effica-
cious against P. falciparum and Plasmodium chabaudi in 
mice with ED90 values of 1 mg/kg and 0.75 mg/kg respec-
tively. In the in vitro and in vivo potency assays that were 
run, P218 was found to be more potent than PYR in all 
cases.
Along with its high potency and good safety profile, 
P218 has the potential to be a replacement for PYR com-
bination with CG in areas where PfDHFR resistance has 
emerged. P218 has currently completed Phase I trials 
(NCT02885506).
Discovered by a partnership between St Jude Children’s 
Research Hospital and Rutgers University in 2010, (+)-
SJ733 (Fig.  20) is a novel tetrahydroisoquinolone car-
boxanilide that possesses excellent anti-malarial activity 
in vivo [99].
High-throughput phenotypic screening of >  300,000 
compounds against the 3D7 strain of P. falciparum dis-
covered a number of bioactive scaffold types, in which 
the hit compound (S′1, Fig.  21), belonging to the tet-
rahydroisoquinolone carboxanilide class, was found to 
have potent in vitro activity (EC50 = 53 nM). Metabolic 
studies using mouse liver microsomes identified the 
susceptibility of the methoxy group to demethylation. 
In order to overcome this issue, the aniline substitu-
ents were replaced with fluoro and cyano groups (S′2), 
which had an added effect of improving the potency 
more than twofold. The thiophene group was suspected 
to be a metabolic hot spot, which was addressed by its 
replacement with a pyridyl group (S′3) resulting also in 
improved solubility, while maintaining potency. The final 
metabolically labile group (isobutyl) was replaced with a 
Fig. 17 Key compounds in the discovery of DM1157. Initial 
combination of the reversal agent, imipramine, with the CQ core 
resulted in the potent RCQ compound D2. Subsequent replacement 
of the reversal agent with 1-(2,2-diphenylethyl)piperazine (D3), and 
further modification with pyridine rings led to improved potency and 
cLogP values for the optimized compound
Fig. 18 Key biological and physical properties of P218 
Fig. 19 Key compounds in the discovery of P218. The key 
2,4-diaminopyrimidine core highlighted in red can be found in a 
number of DHFR inhibitors
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trifluoromethyl moiety, further improving solubility and 
maintaining potency to give the lead compound (+)-
SJ733. The (+)-(3S,4S) isomer was found to be signifi-
cantly more potent (EC50 = 36 nM) than its (–)-(3R,4R) 
enantiomer (EC50 = 587 nM) [100].
In the P. berghei mouse model, (+)-SJ733 was found 
able to cure malaria at doses of 4 × 100 mg/kg and has 
an ED90 of 1.9 mg/kg. It has shown transmission block-
ing activity in infected mice with an ED50 of 5 mg/kg. It 
possesses a good safety profile with no cytotoxicity and 
was found to be more potent in vivo when compared to 
existing anti-malarials such as artesunate, chloroquine, 
and pyrimethamine [101].
The molecular target of (+)-SJ733 has been identified 
as the P-type Na+–ATPase transporter (PfATP4, vide 
infra), which has been implicated as a target for a num-
ber of other structurally diverse compounds [102]. The 
compound is currently in the recruiting stage of first-in-
human study trials (NCT02661373).
ACT-451840 (Fig.  22) is a phenylalanine-based com-
pound that was developed in 2016 through a collabora-
tion between Actelion Pharmaceuticals and the Swiss 
Tropical and Public Health Institute (STPHI). It has the 
potential to be a fast-acting drug with a long half-life and 
has shown efficacy against multiple stages of the P. falci-
parum parasite [103].
Initial erythrocyte-based phenotypic screening of 
∼  5000 compounds identified A′1 (Fig.  23) as a highly 
potent compound against the chloroquine-resistant K1 
strain of P. falciparum (IC50 = 3.8 nM). The SAR studies 
in this project were unique in that the anti-malarial activ-
ity was measured in parallel in two different media: 10% 
bovine serum albumin and 50% human serum, with the 
latter used to help identify any potential problems with 
protein binding at an early stage of the optimization. The 
stereogenic centre of the amino acid residue proved to be 
important for the activity, with the (S)-isomer showing 
more than tenfold higher activity compared to the non-
natural (R)-isomer. Modification of the n-pentyl chain 
to an acylpiperazine group (A′2) resulted in an improve-
ment in the physical and chemical properties of the com-
pound. Replacement of the trifluoromethyl group with 
a tert-butyl group (A′3) led to improved anti-malarial 
activity, especially in the presence of human serum pro-
teins. Final installation of a 4-cyano moiety on the south-
ern phenyl ring gave the highly potent (IC50 = 0.4 nM) 
lead candidate ACT-451840.
Interestingly, all compounds were found to be signifi-
cantly less active against P. berghei than the human para-
site. This is notable since most new anti-malarial drugs 
Fig. 20 Key biological and physical properties of (+)-SJ733. 
Sexual stage potency and logD kindly provided by K. Guy, personal 
communication, 2018
Fig. 21 Key stages in the hit to lead pathway of (+)-SJ733. 
Poor metabolic stability of the hit compound was addressed by 
replacement of the chloro and methoxy groups with cyano and 
fluoro groups respectively. Further in vivo stability and solubility 
improvements were made by changing the thiophene to a 
pyridine. Finally, the gem-dimethyl group was substituted with a 
trifluoromethyl group to eliminate possible metabolic oxidation
Fig. 22 Key biological and physical properties of ACT-451840 
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in development have shown similar potency against both 
rodent and human parasites. As a result, for in vivo stud-
ies it was crucial to use a humanized P. falciparum severe 
combined immunodeficiency (SCID) mouse model. In 
the P. berghei mouse model, ACT-451840 showed the 
ability to cure malaria at doses of 3 × 300 mg/kg with 
an ED90 of 13 mg/kg. In the P. falciparum SCID mouse 
model it had an ED90 of 3.7 mg/kg. The importance of 
the delivery system for ACT-451840 was shown through 
in  vivo experiments: a 60 mg dose in corn oil was as 
effective as a 100 mg dose in a mixture of Tween-EtOH/
water = 10:90.
ACT-451840 has shown activity against multiple par-
asite life cycle stages of both P. falciparum and P. vivax 
[104]. The MoA is suspected to be novel but is currently 
unknown. ACT-451840 last completed first-in-human 
studies in 2014 (NCT02223871) [105] and is currently 
awaiting a decision to proceed.
Product development (patient exploratory)
Discovered in 2011 by a partnership between Monash 
University, the University of Nebraska and the STPHI, 
OZ439 (Fig.  24) is a synthetic trioxolane that possesses 
fast-acting curative and transmission-blocking ability, 
and is active against artemisinin-resistant parasites [106].
The discovery of OZ439 (a.k.a. Artefenomel) stems 
from the lead optimization of the pre-existing trioxolane 
OZ277 (O1, Fig. 25, a.k.a. Arterolane), which was discov-
ered in 2004 [107, 108]. As previous studies have shown 
that the adamantane-peroxide moiety is essential for 
anti-malarial activity, studies were focused on the eastern 
portion of the molecule [109–111]. Notably, analogues 
with variation in this area were found to have largely 
similar in  vitro activities. In order to improve upon the 
original lead compound OZ277 (mean survival 11 days, 0 
from 5 mice cured), replacement of the amide linker with 
a phenyl ether linker (O2) led to improved exposure and 
single-dose curative efficacy (mean survival > 30 days, 5 
from 5 mice cured when applied in single dose of 30 mg/
kg 1 day after infection). An attempt to further improve 
the exposure saw replacement of the alkylamine chain 
with a terminal piperazine unit (O3), however this led 
to a significant reduction in curative efficacy (mean sur-
vival 17 days, 0 from 5 mice cured). Encouragingly, using 
morpholine (OZ439) resulted in a mean survival of > 30 
days, with 5 from 5 mice cured [112]. While OZ439 has 
shown excellent curative efficacy, no clear correlations 
were found between in vitro and in vivo activity or physi-
ochemical properties and exposure. As a result, this new 
lead compound possess significantly lower solubility and 
slightly lower potency than OZ277.
Unlike other peroxide-containing anti-malarials (e.g. 
artemisinin), OZ439 was found to be curative at a sin-
gle dose of 20 mg/kg in the P. berghei mouse model and 
possessed prophylactic activity superior to mefloquine 
when a 30 mg/kg dose was applied 24 h prior to malaria 
infection. OZ439 also showed full anti-malarial protec-
tion when administered 96 h before infection at a dose of 
100 mg/kg. Only minor signs of toxicity were observed 
in a rat model when five consecutive doses of 300 mg/kg 
were administered with 3 days interval. Conversely, O2 
resulted in the death of 9 from 12 animals when used at 
the same dose [112]. OZ439 has shown a significantly 
longer half-life in humans (about 46–62 h) when com-
pared to the hit compound OZ277 (3 h) [113–115].
Much like the current peroxide-containing anti-
malarials, the precise MoA for OZ439 has yet to be 
Fig. 23 Key stages in the hit to lead pathway of ACT-451840. Initial 
change of the n-pentyl group to an acylpiperazine (A′2) helped to 
improve the physicochemical properties. Subsequent introduction of 
a tert-butyl in place of the trifluoromethyl (A′3) and a cyano group on 
the southern phenyl ring resulted in the optimized compound
Fig. 24 Key biological and physical properties of OZ439. In vivo  ED90 
kindly provided by S. Wittlin, personal communication, 2018
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discovered but it is believed that oxidative stress plays a 
major role [116, 117]. First-in-human results for OZ439 
were published in 2013 [118] and since then the mol-
ecule has progressed into Phase IIb clinical trials with 
planned completion in 2019 (NCT02497612) [119].
KAF156 (Fig.  26) was identified in 2008 by Novartis 
and The Scripps Research Institute and is part of the 
second-generation of imidazolopiperazine anti-malarials 
that potentially possesses a novel MoA and performs as a 
rapid-acting drug [120].
A high-throughput screen of 1.7 million compounds in 
a P. falciparum proliferation assay led to the identifica-
tion of hit compound K1 (Fig. 27). In order to protect the 
metabolically vulnerable positions in the lead compound 
and to optimize the potency, the benzodioxole and 
phenyl fragments were replaced with 4-fluorobenzene 
groups (K2). Installation of a dimethyl group in the pip-
erazine ring led to the twofold more potent compound 
KAF156 [121, 122]. Notably, removal of the glycine 
residue from the piperazine ring was shown to increase 
the in vitro potency further (EC50 = 5 nM), but this was 
accompanied by a lower parasitaemia reduction, indi-
cating the importance of the amino acid side chain for 
in vivo efficacy [121].
In the causal prophylactic rodent malaria model, a sin-
gle oral dose of 10 mg/kg administered 2 h before intra-
venous infection with P. berghei sporozoites was shown 
to be fully protective. KAF156 has also shown transmis-
sion blocking ability in the P. berghei model.
The MoA for KAF156 remains unknown. Through the 
culturing of resistant strains, mutations have been iden-
tified in three genes: P. falciparum Cyclic Amine Resist-
ance Locus (PfCARL), UDP-galactose and Acetyl-CoA 
transporters [58, 123]. KAF156 is currently in Phase IIb 
clinical trials, administered in combination with Lume-
fantrine (NCT03167242).
KAE609/Cipargamin/NITD609 (Fig. 28) was discov-
ered by a partnership between Novartis, the STPHI and 
the Wellcome Trust [124, 125].
A high-throughput P. falciparum proliferation assay 
identified a racemic spiroazepineindole compound (K′1, 
Fig.  29) which possessed moderate potency against K1 
and NF54 strains, as well as potent in vivo efficacy. Con-
firmation of the hit result by resynthesis of K′1 resulted 
in the isolation of a ∼ 9:1 diastereomeric ratio favouring 
the (1R,3S) and (1S,3R) pair of enantiomers. Chiral sepa-
ration of this major pair identified the (1R,3S) enantiomer 
K′2 as being >  250-fold more potent than the (1S,3R) 
enantiomer. Reduction of the ring size (K′3) facilitated a 
diastereoselective Pictet–Spengler reaction, which ulti-
mately led to the production of highly potent spiroin-
dolone KAE609.
KAE609 is equipotent against drug-resistant strains 
and was found to be as effective as artesunate against P. 
falciparum and P. vivax isolates [126]. It shows a good 
safety profile, with low cytotoxicity, cardiotoxicity and 
mutagenic activity, and is able to clear parasitaemia rap-
idly in adults with uncomplicated P. falciparum or P. 
vivax malaria at a dose of 30 mg/day for 3 days. KAE609 
displays low clearance from the body, has a long half-life 
and excellent bioavailability.
KAE609 is one of the key novel compounds that has 
been found to act through inhibition of PfATP4 (vide 
infra). Along with a number of other structurally distinct 
compounds that are also thought to inhibit PfATP4 as 
their MoA, KAE609 has shown great promise as an new 
anti-malarial candidate and is currently in Phase IIb trials 
(NCT03334747).
DSM265 (Fig. 30) was discovered through a collabora-
tion between the University of Texas Southwestern, the 
University of Washington and Monash University [127].
Fig. 25 Key stages in the hit to lead pathway of OZ439. Initial 
replacement of the amide linker with a phenyl ether linker resulted 
in improved exposure while maintaining potency (O2). The exposure 
was further improved by changing the alkylamine chain to a 
piperazine ring (O3). Final replacement of the piperazine ring with 
a morpholine unit led to the optimized compound OZ439, which 
possessed better curative efficacy in vivo
Fig. 26 Key biological and physical properties of KAF156. Solubility 
and logD kindly provided by T. Diagana, personal communication, 
2018
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Identified in a high-throughput screen of P. falcipa-
rum dihydroorotate dehydrogenase (PfDHODH)-based 
enzyme activity, the selective inhibitor D′1 (Fig. 31) was 
found. The compound showed high potency but was rap-
idly metabolized and was inactive in vivo. Substitution of 
the naphthyl ring with a trifluoromethylphenyl group led 
to a metabolically stable analogue (D′2). Examination of 
the bound crystal structures of D′1 and D′2 with PfD-
HODH identified key residue interactions which eventu-
ally led to the installation of a difluoroethyl group (D′3) 
which significantly improved the potency and solubility. 
Final modification of the trifluoromethyl group with a 
pentafluorosulfur group led to the optimized compound 
DSM265.
DSM265 has been shown to be a highly selective 
inhibitor of malarial DHODH and is potent against both 
blood and liver stages of P. falciparum and also drug-
resistant parasite isolates. It has an excellent safety profile 
(provides therapeutic concentrations after 8 days of a sin-
gle oral dose, tolerated in repeat-doses, non-mutagenic, 
inactive against human enzymes/receptors) and has a 
very low clearance rate and a long half-life in humans 
[128]. DSM265 has completed Phase IIa trials in Peru in 
patients with P. falciparum or P. vivax (NCT02123290) 
and also completed a controlled human malaria infection 
study in combination with OZ439 (NCT02389348).
Identified in 2012 by a team at the University of Cape 
Town, South Africa in the same campaign as UCT943, 
MMV048 (Fig. 32) is another compound in the 3,5-dia-
ryl-2-aminopyridine class that possesses good prophylac-
tic activity against Plasmodium cynomolgi in vivo and has 
the potential to act as a transmission-blocking drug [84].
The initial hit (M″1, Fig.  33) showed potent in  vitro 
activity against the NF54 (drug-sensitive) strain of P. fal-
ciparum (IC50 = 49 nM) but suffered from poor solubil-
ity and high metabolic clearance. The metabolically labile 
3-methoxy-4-hydroxyphenyl moiety was replaced by a 
methoxypyridyl ring giving the more stable and equipo-
tent compound M″2. Further SAR studies revealed that 
replacement of the methoxy group by a trifluorome-
thyl group led to the improved potency and stability of 
MMV048.
MMV048 has shown 99.3% reduction in parasitaemia 
in the P. berghei mouse model at a single dose of 30 mg/
kg with no signs of parasites after 30 days (ED90 = 1.7 
mg/kg). This highlights the potential of MMV048 to act 
as a single dose treatment.
The target of MMV048 is PfPI4K, which was recently 
revealed as a new MoA for anti-malarial drugs (vide 
infra) [87]. MMV048 is currently in Phase IIa clinical tri-
als in Ethiopia [58].
Modes of action
The continual emergence of drug resistant Plasmodium 
strains means that developing new drugs with novel 
MoAs is important [129]. Below, are summarized some 
newer MoAs that are currently being pursued and which 
are exemplified by the compounds described above.
Translational elongation factor 2 (PfeEF2) inhibitor
The P. falciparum translational elongation factor 2 
(PfeEF2) is one of the essential factors for eukaryotic pro-
tein synthesis, catalysing the translocation of tRNA and 
mRNA [130]. The overall efficacy of drugs that target this 
elongation factor may be increased due to PfeEF2 being 
expressed in multiple stages of the parasite life-cycle [78].
M5717 has been shown to inhibit PfeEF2 as its MoA, 
but a binding pocket for M5717 could not be elucidated 
from the modelling studies [78]. This MoA was found by 
culturing blood stage parasites with five times the EC50 
of M5717, leading to resistance in the 3D7, 7G8 and 
Fig. 27 Key stages in the hit to lead pathway of KAF156. Potential 
metabolic stability issues were addressed through fluorine 
bioisosteres giving K2. Introduction of a dimethyl group on the 
piperazine ring resulted in increased potency and led to the 
optimized compound
Fig. 28 Key biological and physical properties of KAE609. 
*Significant inhibition at 50 and 500 nM doses
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Dd2 strains. Through whole-genome sequencing of these 
resistance lines, a common mutation was found which 
identified PfeEF2 as the target.
P-type Na+–ATPase inhibitor (PfATP4) inhibitor
The malaria parasite must maintain a low intracellular 
Na+ concentration to survive, especially in the presence 
of the high concentration of extracellular sodium ions. 
In this case, the parasite’s influx of Na+ is regulated by 
using a P-type ATPase transporter (PfATP4) that shuttles 
sodium ions out of the cell. Inhibition of this transporter 
results in a build up of Na+ inside the parasite, ultimately 
leading to cell death [102].
A number of structurally diverse compounds (includ-
ing (+)-SJ733 and KAE609) are thought to target 
PfATP4 as their MoA again suggested by the develop-
ment of resistant mutants and sequencing [124]. The Kirk 
group have developed a fluorescence assay for this MoA 
[131], which has been used by the OSM project to impli-
cate PfATP4 as a MoA for the Series 4 triazolopyrazines 
[132]. Of note, however, is that this MoA is suggested for 
a very broad range of chemotypes [133, 134], and there 
is no direct evidence for binding of these compounds to 
PfATP4, the structure of which remains unsolved.
V-type H +–ATPase inhibitor
At the same time that the parasite is regulating its Na+ 
concentration through the above mechanism, it also 
imports H + through the same pathway. To regulate this 
increasing H + concentration and maintain an intracellu-
lar pH of ∼ 7.3, the parasite uses a complementary V-type 
ATPase transporter to efflux H + [135].
MMV253 has been shown to inhibit the V-type H + 
ATPase as its MoA through mutant selection and whole-
genome sequencing [81].
Phosphatidylinositol 4-kinase (PfPI4K) inhibitor
Phosphatidylinositol 4-kinase (PI4K) is a eukaryotic 
enzyme that phosphorylates lipids, allowing them to 
regulate intracellular signalling and trafficking [87]. Inhi-
bition of the ATP-binding pocket of PI4K leads to disrup-
tion of the intracellular distribution of PI4-phosphate 
(PI4P), which in turn results in decreased late-stage para-
site development.
By culturing resistant lines and identifying the genomic 
mutations, two compounds (UCT943 and MMV048) 
have been found to inhibit the PfPI4K enzyme [87].
Dihydroorotate dehydrogenase (PfDHODH) inhibitor
To be able to replicate in the human erythrocyte, the 
Plasmodium parasite requires pyrimidines, which are 
essential metabolites in all cells. As the parasite is unable 
to use endogenous pyrimidines, it must synthesize them 
de novo. A key step in the biosynthesis of pyrimidines 
is the oxidation of dihydroorotate to produce orotate, a 
reaction that is catalysed by the enzyme dihydroorotate 
dehydrogenase (DHODH). By inhibiting this enzyme, 
the malaria parasite can no longer obtain the required 
metabolites to survive, and is killed [136].
The P. falciparum D10 strain (chloroquine sensitive) 
has been known to be less susceptible to  bc1 complex 
inhibitors and PfDHODH inhibitors. Addition of progua-
nil to this strain is known to restore the sensitivity to  bc1 
complex inhibitors but not to PfDHODH inhibitors. This 
cell line was found to be resistant to DSM265, regardless 
Fig. 29 Key stages in the hit to lead pathway of KAE609. Resolution 
of the initial racemic hit (K′1) gave the significantly more potent 
stereoisomer (K′2). Reducing the ring size further increased the 
potency and final halogenation of the indole ring led to the 
optimized compound KAE609 
Fig. 30 Key biological and physical properties of DSM265 
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of whether proguanil was present or not, which identifies 
inhibition of PfDHODH as its MoA [127, 137].
Dihydrofolate reductase (PfDHFR) inhibitor
Similar to the above case, the malaria parasite also 
requires folates in order to maintain their high rate 
of replication. The parasite is able to scavenge folates 
or synthesize them de novo. Dihydrofolate reductase 
(DHFR) is an enzyme that catalyses a step required for 
the recycling of folates, which in turn are used in the syn-
thesis of thymidylate, purines and methionine [138].
PfDHFR is a known target of a number of well known 
antifolate anti-malarial drugs including cycloguanil and 
pyrimethamine. Through examinations of the key inter-
actions in the cocrystal structure of known inhibitors 
with the enzyme, P218 was designed as a potent inhibi-
tor [98].
Conclusions
Although the rate of malaria related deaths has declined 
over the past few years, the progress is beginning to slow. 
With the recent emergence of resistance to current front-
line artemisinin-based combination therapy, the need for 
the discovery of new anti-malarials that can act through 
novel mechanisms of action has been pushed firmly to 
the top of the development agenda.
Over the past few years, high-throughput screens have 
identified a number of novel chemotypes that have since 
been developed into highly promising anti-malarial can-
didates. Crucially, many of these compounds have dem-
onstrated novel MoAs which are essential if future drugs 
are to succeed. This is wonderful progress, and testament 
to the hard work of the groups involved.
The discovery of these novel MoAs will pave the way 
for the development of future anti-malarials. The explo-
ration of further novel MoAs has become a possibility 
through the use of in vitro evolution and whole-genome 
analysis (IVIEWGA), which uses genome-base target dis-
covery methods on compounds identified from the more 
common phenotypic screens [139]. In all such future 
development, creativity and ingenuity in the hit to lead 
Fig. 31 Key stages in the hit to lead pathway of DSM265. 
Replacement of the second phenyl ring in the naphthyl group 
with a trifluoromethyl group improved solubility. Addition of a 
1,1-difluoroethyl group significantly increased the potency and 
final replacement of the trifluoromethyl group in D′2 with a 
pentafluorosulfur moiety led to the optimized compound DSM265 
Fig. 32 Key biological and physical properties of MMV048 
Fig. 33 Key stages in the hit to lead pathway of MMV048. Initial 
replacement of the 3-methoxy-4-hydroxyphenyl moiety helped to 
improve in vivo stability and solubility. Further replacement of the 
methoxy group with a trifluoromethyl group improved potency and 
metabolic stability leading to the optimized compound
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campaigns will continue to be needed if people are to 
remain able to combat this formidable disease.
The pace of research progress is high, meaning updates 
to reviews such as this will always be needed (Additional 
file 3). It is proposed that derivatives of this open access 
review, combined with data in relevant databases such 
as the one currently in development by the Guide to 
Pharmacology [140], could aim to serve as more “living” 
sources of information for compounds in development 
and their potential targets.
Additional files
Additional file 1. Compounds reference list. List of SciFinder reference 
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Additional file 2. Biological data for compounds. Tabulation of biological 
potencies and pharmacokinetic properties for each compound described 
in Future section of this review.
Additional file 3. SMILES strings and CID numbers for compounds. List 
of SMILES strings and CID numbers for every compound described in this 
review.
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